Australia markets open in 9 hours 53 minutes

Biohaven Ltd. (BHVN)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
38.990.00 (0.00%)
As of 10:05AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close38.99
Open39.70
Bid39.09 x 800
Ask39.36 x 1100
Day's range38.75 - 39.65
52-week range12.35 - 62.21
Volume114,177
Avg. volume1,268,806
Market cap3.19B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-5.73
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est59.50
  • PR Newswire

    Biohaven Announces Pricing of $230 Million Public Offering of Common Shares

    Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology, today announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share. In addition, Biohaven has granted the underwriters a 30-day option to purchase up to an additional 841,463 common shares at the public

  • PR Newswire

    Biohaven Announces Proposed Public Offering of Common Shares

    Biohaven Ltd. (NYSE: BHVN), a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience and oncology, today announced that it has commenced an underwritten public offering of $200 million of its common shares. All of the common shares to be sold in the offering will be offered by Biohaven. In addition, Biohaven expects to grant the underwriter a 30-day option to purchase up to an

  • PR Newswire

    Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates

    Biohaven Ltd. (NYSE: BHVN) announced today that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology (AAN) Annual Meeting, taking place in Denver, Colorado. The presentations highlight Biohaven's leadership in neuroscience and extensive development programs evaluating novel therapies to treat neurological diseases, with abstracts covering programs that include Kv7 ion channel modulation, molecular